Trending...
- Maryland Market Money Program Transitions to the Maryland Department of Agriculture
- Santa Monica Businesses Push Back on Bus Stop Relocation That Threatens Access and Safety
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
BALTIMORE, April 10, 2021 /PRNewswire/ -- Sysmex Inostics, Inc., a global leader of the liquid biopsy revolution for oncology, is presenting the poster "Clinical evaluation of NGS-based liquid biopsy testing in non-small cell lung cancer (NSCLC) patients" at the 112th Annual Meeting of the American Association for Cancer Research on April 10, 2021, from 8:30 AM - 11:59 PM Eastern Daylight Time (EDT).
In a recent collaborative study, Johns Hopkins University School of Medicine and Sysmex Inostics' researchers showed that the next-generation sequencing (NGS)-based liquid biopsy SafeSEQ NSCLC panel delivers equivalent performance with broader genomic coverage than testing with OncoBEAM™ digital PCR (dPCR). OncoBEAM technology is widely considered a gold standard for high sensitivity molecular testing and continues to be one of the most sensitive dPCR approaches.
SafeSEQ technology demonstrates ultra-sensitive detection of low-frequency mutations, with a calling threshold of 5 mutant molecules (0.025% mutant allele frequency [MAF]) from whole blood. Concordance analysis of SafeSEQ and OncoBEAM results demonstrated an overall percent agreement of 99.6% for detection of mutations in EGFR, KRAS, and BRAF (>0.1% MAF).
The 5-year survival rate for metastatic NSCLC (mNSCLC) patients is relatively low; however, it has improved with the advent of targeted therapies and uptake of circulating tumor DNA (ctDNA) based technologies in recent years. In groundbreaking NSCLC clinical trials AURA and TIGER-X, patients positive for EGFR T790M detected in plasma by OncoBEAM had equivalent outcomes to patients positive by a tissue-based assay when treated with third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), which have demonstrated potent activity against first-line EGFR TKI resistance mediated by EGFR T790M.
More on Marylandian
SafeSEQ NSCLC testing delivers broader genomic coverage than OncoBEAM, with the same ultra-sensitive detection for rare mutant molecules. Therefore, SafeSEQ is better suited to identify molecular mediators of treatment resistance to improve therapeutic strategies, delivering high-resolution monitoring of therapeutic efficacy, and enabling minimum residual disease (MRD) detection and recurrence surveillance for NSCLC patients.
Poster number LB053, "Clinical evaluation of NGS-based liquid biopsy genotyping in non-small cell lung cancer (NSCLC) patients," presented by Hillary Sloane, Associate Director of Medical & Scientific Affairs at Sysmex Inostics, will be available Saturday, April 10, 2021, from 8:30 AM - 11:59 PM EDT during the 112th Annual Meeting of the American Association for Cancer Research during Session PO.CL11.04 - Liquid Biopsies: Circulating DNA.
AURA Trial: Oxnard, GR, et al. J Clin Oncol 2016, 34 (28), 3375–82.
TIGER-X Trial: Karlovich, C, et al. Clin Cancer Res 2016, 22 (10), 2386–95.
About Sysmex Inostics
Sysmex Inostics, a Sysmex Corporation subsidiary, empowers discoveries in oncology by providing investigators cost-effective and ultra-sensitive quantitative liquid biopsy solutions SafeSEQ (NGS), and OncoBEAM™ (digital PCR).
Developed by experts at Johns Hopkins with the philosophy of "no molecule left behind," these technologies are optimized to ensure the detection of low-frequency mutant molecules (<0.05% MAF) with a high degree of specificity. Focused and flexible genomic coverage allows for superior sensitivity and reduced costs.
More on Marylandian
As pioneers in blood-based circulating tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last ten years to help develop therapeutics to extend lives and companion diagnostics to monitor progression, identify targetable resistance alterations, and detect minimal residual disease (MRD).
Sysmex Inostics' SafeSEQ and OncoBEAM services are readily available and customizable to support clinical trials and research in oncology. OncoBEAM™ tests are available through a CLIA-certified laboratory for routine clinical analysis and distributed kit products in the E.U.
Sysmex Inostics' European headquarters for research & development GCP laboratory testing are located in Hamburg, Germany; Sysmex Inostics' U.S. headquarters and CLIA-certified and GCP Clinical Laboratory is located in Baltimore, Maryland.
For more information, refer to www.sysmex-inostics.com or email [email protected]
Press Contact:
Tracy Vandenbroek
Sysmex Inostics
Director, Marketing
[email protected]
+1-512-791-2899
SOURCE Sysmex Inostics GmbH
In a recent collaborative study, Johns Hopkins University School of Medicine and Sysmex Inostics' researchers showed that the next-generation sequencing (NGS)-based liquid biopsy SafeSEQ NSCLC panel delivers equivalent performance with broader genomic coverage than testing with OncoBEAM™ digital PCR (dPCR). OncoBEAM technology is widely considered a gold standard for high sensitivity molecular testing and continues to be one of the most sensitive dPCR approaches.
SafeSEQ technology demonstrates ultra-sensitive detection of low-frequency mutations, with a calling threshold of 5 mutant molecules (0.025% mutant allele frequency [MAF]) from whole blood. Concordance analysis of SafeSEQ and OncoBEAM results demonstrated an overall percent agreement of 99.6% for detection of mutations in EGFR, KRAS, and BRAF (>0.1% MAF).
The 5-year survival rate for metastatic NSCLC (mNSCLC) patients is relatively low; however, it has improved with the advent of targeted therapies and uptake of circulating tumor DNA (ctDNA) based technologies in recent years. In groundbreaking NSCLC clinical trials AURA and TIGER-X, patients positive for EGFR T790M detected in plasma by OncoBEAM had equivalent outcomes to patients positive by a tissue-based assay when treated with third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), which have demonstrated potent activity against first-line EGFR TKI resistance mediated by EGFR T790M.
More on Marylandian
- Maryland State Board of Veterinary Medical Examiners Meeting Notice
- California Family Launches Billboard to Reach "Pardon Czar" Alice Marie Johnson
- Rent Like A Champion Acquires CollegeWeekends
- Sumter Landing Dental Care Launches Summer Special on Full Mouth Reconstruction
- Seligson Law Launches New Website to Support Cannabis Businesses in California and New York
SafeSEQ NSCLC testing delivers broader genomic coverage than OncoBEAM, with the same ultra-sensitive detection for rare mutant molecules. Therefore, SafeSEQ is better suited to identify molecular mediators of treatment resistance to improve therapeutic strategies, delivering high-resolution monitoring of therapeutic efficacy, and enabling minimum residual disease (MRD) detection and recurrence surveillance for NSCLC patients.
Poster number LB053, "Clinical evaluation of NGS-based liquid biopsy genotyping in non-small cell lung cancer (NSCLC) patients," presented by Hillary Sloane, Associate Director of Medical & Scientific Affairs at Sysmex Inostics, will be available Saturday, April 10, 2021, from 8:30 AM - 11:59 PM EDT during the 112th Annual Meeting of the American Association for Cancer Research during Session PO.CL11.04 - Liquid Biopsies: Circulating DNA.
AURA Trial: Oxnard, GR, et al. J Clin Oncol 2016, 34 (28), 3375–82.
TIGER-X Trial: Karlovich, C, et al. Clin Cancer Res 2016, 22 (10), 2386–95.
About Sysmex Inostics
Sysmex Inostics, a Sysmex Corporation subsidiary, empowers discoveries in oncology by providing investigators cost-effective and ultra-sensitive quantitative liquid biopsy solutions SafeSEQ (NGS), and OncoBEAM™ (digital PCR).
Developed by experts at Johns Hopkins with the philosophy of "no molecule left behind," these technologies are optimized to ensure the detection of low-frequency mutant molecules (<0.05% MAF) with a high degree of specificity. Focused and flexible genomic coverage allows for superior sensitivity and reduced costs.
More on Marylandian
- databahn Announces Subscription Access to Fortune 500 GenAI Deep Dive Sales Intelligence Reports
- AI startup Congero offers instant websites with 24/7 updates - aiming to replace web agencies
- WonderDays Launches the UK's First AI Experience Gift Finder – Gifting Just Got So Much Easier!
- CelluHeal™ Launches Full Line of Advanced Wound Dressings for Online Purchase in the USA, Canada, and Beyond
- Nonprofit innovator named Mensa Executive Director
As pioneers in blood-based circulating tumor DNA (ctDNA) mutation detection, Sysmex Inostics has provided custom assays and CLIA-certified lab services to leading BioPharma companies over the last ten years to help develop therapeutics to extend lives and companion diagnostics to monitor progression, identify targetable resistance alterations, and detect minimal residual disease (MRD).
Sysmex Inostics' SafeSEQ and OncoBEAM services are readily available and customizable to support clinical trials and research in oncology. OncoBEAM™ tests are available through a CLIA-certified laboratory for routine clinical analysis and distributed kit products in the E.U.
Sysmex Inostics' European headquarters for research & development GCP laboratory testing are located in Hamburg, Germany; Sysmex Inostics' U.S. headquarters and CLIA-certified and GCP Clinical Laboratory is located in Baltimore, Maryland.
For more information, refer to www.sysmex-inostics.com or email [email protected]
Press Contact:
Tracy Vandenbroek
Sysmex Inostics
Director, Marketing
[email protected]
+1-512-791-2899
SOURCE Sysmex Inostics GmbH
Filed Under: Business
0 Comments
Latest on Marylandian
- Ironside HR Named Fastest-Growing Staffing Firm for Second Year
- Inframark Continues to Build Its Community Management Capabilities and Multi-Disciplinary Presence in Arizona
- ICAST 2025: The Crystal-Clear Revolution Begins at Booth #3233
- Burned-Out to Breakthrough: How Pain 2 Prosperity Authors Illuminate Founder Resilience
- Brindle Pet Supplies Now Carries Badlands Ranch Dog Food in Canada
- $10 Million Allocated to Establish Crypto Treasury Focused on High Value Ethereum (ETH) & Bitcoin (BTC) as Long-Term Holdings for Cybersecurity Leader
- Sing For Your Supper: A Night of Musical Comedy and Drag for a Great Cause
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $100 to $200 Million Equity Agreement with Top Digital Advisor Bitwise to Power Major Digital Asset Initiative for Bitcoin and Solana: OFA Group
- InSpired Brings World Premiere to the Weinberg Center This October
- New Collaboration Launches Corporate ESG Solution for Responsible Decommissioning and Transparent Reporting
- SlickCashLoan Launches Free Loan Calculator to Help You Plan Monthly Payments
- TikTok Star ArcadeFriends Attempts 24-Hour Claw Machine Marathon at Lucky Puppy Arcade in Las Vegas
- Pyro Marketing Launches New Website to Accelerate Growth for Fitness Brands
- Allison Transmission partners with Maryland Transit Administration to bring eGen Flex®-Equipped Electric Hybrid Buses to Baltimore
- KCON LA 2025, 106.3 RAIN FM 'Take Over' Special Event
- The Citizens Commission on Human Rights Annual Purple Heart Day Event will be Hosted at the Historic Fort Harrison
- Blake Harris the Leading Authority in International Asset Protection Joins Tom Hegna on "Financial Freedom with Tom Hegna"
- Maryland Market Money Program Transitions to the Maryland Department of Agriculture
- Third Annual African American Cultural Expo and Children's Book Fair Comes to Waldorf, MD